 |  |
Inflavonoid Intensive Care, Metagenics
 |
|
 | Product Name: Inflavonoid Intensive Care
Manufacturer: Metagenics Item #: NF009 Content: 90 Tabs
Check Price >>
|
Standardized Herbal Relief for Minor Pain
Inflavonoid Intensive Care provides the same great ingredients and benefits as original Inflavonoid®, but with added support for those who want a more aggressive approach. To maximize the benefits of this unique formulation, Inflavonoid Intensive Care:
- Features an extract of boswellia, as well as turmeric and ginger; all premium quality and standardized to key compounds to ensure effectiveness, reproducibility, and consistent results.
- Provides cayenne, an herb that has long been prized for its many health benefits such as the relief of minor pain, which complements the activity of the other herbs.
- Offers added antioxidant support from quercetin.
- Provides excellent muscle tissue support and relief of minor pain following intense exercise or "weekend warrior" syndrome.
Recommendations: Two tablets three times daily. May use two tablets every two hours as needed.
Warning: If pregnant or nursing, or taking medication, consult your healthcare practitioner before use.
Suitable for vegetarians
| Supplement Facts (Inflavonoid Intensive Care) | |
Container Size 90 Tabs | | Serving Size 2 Tabs |  | | | Amount Per 2 Tabs | Content | %DV | | |  | | | Lemon Bioflavonoid Complex [Standardized to 50% (100 mg) full spectrum bioflavonoids] | 200 mg | | | | Quercetin | 100 mg | | | | Vitamin C (as ascorbic acid) | 200 mg | | | | Boswellia Gum Extract (Boswellia serrata) [Standardized to 70% (280 mg) boswellia acids] | 400 mg | | | | Turmeric Rhizome Extract (Curcuma longa) [Standardized tp 95% (285 mg) curcuminoids] | 300 mg | | | | Ginger Rhizome Extract (Zingiber officinale) [Standardized to 5% (10 mg) gingerols] | 200 mg | | | | Cayenne Pepper Fruit (Capsicum annuum) | 50 mg | | | |  | | | U.S. Patent No. 6,534,086. |  | | | % Daily Values (DV) are based on a 2,000 calorie diet. * Daily Value (DV) not established. |
|
|
|
|
|  |  |
|
|
|